Septerna Selects SEP-204 as Development Candidate for Graves’ Disease and TED
Septerna also reports preclinical data at the 2026 American Thyroid Association Annual Meeting.
Septerna also reports preclinical data at the 2026 American Thyroid Association Annual Meeting.